Skip to search formSkip to main contentSkip to account menu

dexloxiglumide

Known as: (R)-4-(3,4-Dichlorobenzamido)-N-(3-Methoxypropyl)-N-pentylglutaramic Acid, CR 2017, CR-2017 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Pentanoic Acids

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Effect of selective CCK1 receptor antagonism on accommodation and tolerance of intestinal gas in functional gut disorders
Participants with functional gut disorders develop gas retention and symptoms in response to intestinal gas loads that are well… 
2008
2008
Duodenal phytohaemagglutinin (red kidney bean lectin) stimulates gallbladder contraction in humans
Aim:  Lectins, carbohydrate‐specific proteins without enzymatic activity on the ligand, are daily ingested plant proteins which… 
Review
2006
Review
2006
Pharmacokinetic Profile of Dexloxiglumide
Dexloxiglumide is a potent and selective cholecystokinin type 1 (CCK1) receptor antagonist currently under development in a… 
2005
2005
Pharmacological analysis of CCK2 receptors up-regulated using engineered transcription factors
2005
2005
Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide.
AIMS Dexloxiglumide is a new CCK(1) receptor antagonist under investigation for treatment of functional gastrointestinal… 
2003
2003
Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects
1. Mean concentrations of total 14 C and of dexloxiglumide at the end of single 20-min infusion doses of 14 C-dexloxiglumide (200… 
2003
2003
Characterization of dexloxiglumide in vitro biopharmaceutical properties and active transport.
The objective of this work was to characterize dexloxiglumide biopharmaceutical properties in vitro and relate these… 
Review
2002
Review
2002
Dexloxiglumide Rotta Research Lab.
Dexloxiglumide, the (R)-isomer of loxiglumide, is a selective and highly potent CCK1 receptor antagonist. It is twice as potent… 
2002
2002
Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
OBJECTIVE To assess the pharmacokinetics, safety and tolerability of dexloxiglumide, a new CCK1 receptor antagonist currently… 
1996
1996
Effect of dexloxiglumide and spiroglumide, two new CCK‐receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo.
BACKGROUND: Clear definition of the role of CCK in the physiology of gastric motor activity has been long hampered by the lack of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)